Cited by 30Alzheimer's disease research and treatmentsMedicinal Plants and NeuroprotectionCholinesterase and Neurodegenerative Diseases

Effect and mechanism of fuzhisan and donepezil on the sirtuin 1 pathway and amyloid precursor protein metabolism in PC12 cells

Open access
GUO, PENG, WANG, DESHENG, WANG, XIAOMIN, FENG, HONGLIN, TANG, YING, SUN, RUIHONG, ZHENG, YAN, DONG, LIN +4 more·2016·Molecular Medicine Reports

Abstract

The present study aimed to determine the effect and mechanism of fuzhisan (FZS) and donepezil on the SIRT1 signaling pathway and the metabolism of the amyloid precursor protein (APP) in PC12 cells. An experimental cell model of PC12 cells with Aβ25‑35‑induced neurotoxicity was established and cell proliferation was determined by the MTT assay following treatment with donepezil and FZS. In addition, cell apoptosis was determined using DAPI staining and light microscopy. Furthermore, western blot analysis and ELISA were utilized to evaluate the expression levels of associated APP, Aβ40, Aβ42, sAPPα, sAPPβ, ADAM10, sirtuin 1 (SIRT1) and forkhead box O (FoxO) protein. The results indicated that the cell model was successfully established and FZS protected the PC12 cells from the neurotoxic effects of Aβ25‑35, in a similar effect to donepezil, in a dose‑dependent manner. The expression of APP remained at the same level during the experimental period. The levels of Aβ40, Aβ42 and sAPPβ were downregulated, where as sAPPα, ADAM10, SIRT1 and FoxO expression levels were upregulated. In conclusion, FZS treatment attenuated the Aβ25‑35‑induced neurotoxicity in vitro. The neuroprotective mechanism of FZS was determined, including the induction of ADAM10 and SIRT1‑FoxO pathway, which participated in the process of neuroprotection. The present study identified the neuroprotective function of FZS, which may protect against Aβ‑induced toxicity. Therefore, FZS may be used clinically as a beneficial therapeutic drug for the development or progression of Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/mmr.2016.4957

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fuzhisan inhibits Abeta25-35-induced neurotoxicity.

    “Consequently, studies have shown that Fuzhisan inhibits Abeta25-35-induced neurotoxicity, with the induction of the ADAM10 and SIRT1-Fox0 pathway serving a potential role in neuroprotection, since PC12 cells treated with Fuzhisan demonstrated significantly elevated levels of ADAM10 [170].”
  • PC12 cells treated with Fuzhisan demonstrated significantly elevated levels of ADAM10.

    “Consequently, studies have shown that Fuzhisan inhibits Abeta25-35-induced neurotoxicity, with the induction of the ADAM10 and SIRT1-Fox0 pathway serving a potential role in neuroprotection, since PC12 cells treated with Fuzhisan demonstrated significantly elevated levels of ADAM10 [170].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
GUO, P., WANG, D., WANG, X., FENG, H., TANG, Y., SUN, R., ZHENG, Y., DONG, L., ZHAO, J., ZHANG, X., WANG, S., & SUN, H.
Affiliations
  • Harbin Medical University (CN)
  • Capital Medical University (CN)
Venue
Molecular Medicine Reports
Published
2016-03-01
Volume
13
Issue
4
Pages
3539-3546
ISSN
  • 1791-2997 (ISSN-L)
  • 1791-3004
OpenAlex
W2290097945
Cited by
30
References
36
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 8 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 2 · 2016: 3
FWCI
2.68
Type
journal article
Language
en
Open access
Locations
  • Molecular Medicine Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
donepezil, SIRT1, APP processing, ADAM10, FOXO, neuroprotection, Alzheimer's disease, PC12 cells, apoptosis, sAPPα, sAPPβ
MeSH terms
ADAM10 Protein, Donepezil, Animals, Drugs, Chinese Herbal, Enzyme-Linked Immunosorbent Assay, Indans, Piperidines, Blotting, Western, Signal Transduction, PC12 Cells, Rats, Forkhead Transcription Factors, Amyloid Precursor Protein Secretases, Sirtuin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review